SAUHF:OTC-Straumann Holding AG (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 167.98

Change

0.00 (0.00)%

Market Cap

USD 26.17B

Volume

1.60K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implants and components made from titanium, titanium alloy, and ceramics; prosthetic elements made od ceramics, metal or polymer; and clear aligners. In addition, it offers resins for 3D printing and thermoplastics for clear aligner production; and biomaterials for tissue generation. Further, it provides digital equipment comprising scanners, milling machines and 3D printers. Further, it offers training and education services. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 108.14B
ESLOY Essilor International SA

N/A

USD 106.30B
HOCPF HOYA Corporation

N/A

USD 49.96B
HOCPY Hoya Corp

N/A

USD 49.96B
CLPBY Coloplast A

-0.16 (-1.23%)

USD 29.67B
CLPBF Coloplast A/S

N/A

USD 29.67B
TRUMF Terumo Corporation

-1.19 (-6.15%)

USD 29.21B
OCPNF Olympus Corporation

N/A

USD 22.43B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.85B
SDMHF Sartorius Stedim Biotech S.A

-17.55 (-8.24%)

USD 20.72B

ETFs Containing SAUHF

IDLB 0.00 % 0.00 %

N/A

N/A
FEQD:LSE Fidelity Europe Quality I.. 0.00 % 0.00 %

+0.03 (+0.43%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.40% 64% D 56% F
Dividend Return 0.29% 24% F 6% D-
Total Return 5.69% 63% D 55% F
Trailing 12 Months  
Capital Gain 33.53% 73% C 76% C+
Dividend Return 0.36% 24% F 11% F
Total Return 33.89% 72% C 74% C
Trailing 5 Years  
Capital Gain 110.21% 94% A 87% B+
Dividend Return 3.30% 6% D- 13% F
Total Return 113.51% 90% A- 85% B
Average Annual (5 Year Horizon)  
Capital Gain 19.21% N/A N/A 64% D
Dividend Return 19.68% N/A N/A 62% D
Total Return 0.47% N/A N/A 13% F
Risk Return Profile  
Volatility (Standard Deviation) 44.59% N/A N/A 55% F
Risk Adjusted Return 44.13% N/A N/A 81% B-
Market Capitalization 26.17B 87% B+ 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.